PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 4.90 ▲ 0.03 (0.62%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Lexicon Pharmaceuticals Inc | LXRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.64 | 15.13% | 4.87 | 5.13 | 4.20 | 4.25 | 4.23 | 23:59:40 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.81 | 5.24 | 0.43 | 8.21% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 19,866 | 4,420,436 | $ 4.75 | $ 20,999,275 | 1,219,714 | 1.125 - 8.55 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:58:21 | formt | 100 | $ 4.90 | USD |
Lexicon Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 517.54M | 106.27M | $ -120.55M | -1.14 | - | 103.75M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 124.00 | 2.40% |
Lexicon Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/05/2019 | 07:00 | GlobeNewswire Inc. | Lexicon Pharmaceuticals Announces Positive Topline Phase 1.. |
| 12/03/2019 | 07:00 | GlobeNewswire Inc. | Lexicon Pharmaceuticals Completes Safety Review of Initial.. |
| 12/02/2019 | 07:00 | GlobeNewswire Inc. | Lexicon Pharmaceuticals Receives Formal Dispute Resolution.. |
| 11/26/2019 | 16:01 | GlobeNewswire Inc. | Lexicon Pharmaceuticals to Present at Upcoming Investor.. |
| 11/19/2019 | 06:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 11/14/2019 | 20:09 | GlobeNewswire Inc. | Lexicon Pharmaceuticals to Present at Upcoming Investor.. |
| 11/07/2019 | 16:34 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.55 | 5.13 | 1.77 | 3.66 | 2,056,618 | 1.32 | 37.18% |
| 1 Month | 3.76 | 5.13 | 1.77 | 3.66 | 1,453,694 | 1.11 | 29.52% |
| 3 Months | 2.37 | 5.13 | 1.77 | 3.49 | 1,965,375 | 2.50 | 105.49% |
| 6 Months | 5.66 | 6.72 | 1.125 | 2.86 | 1,690,843 | -0.79 | -13.96% |
| 1 Year | 7.34 | 8.55 | 1.125 | 3.87 | 1,237,236 | -2.47 | -33.65% |
| 3 Years | 14.44 | 18.00 | 1.125 | 8.31 | 849,091 | -9.57 | -66.27% |
| 5 Years | 0.95 | 19.62 | 0.80 | 8.18 | 929,976 | 3.92 | 412.63% |
Lexicon Pharmaceuticals Description
| Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211. |
